AstraZeneca receives CDSCO panel nod to conduct phase 3 trial of Trastuzumab Deruxtecan
In a significant development, major drug-maker AstraZeneca has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) to conduct a Phase 3 clinical trial of oncology drug Trastuzumab Deruxtecan, which is an antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer.This comes in...
In a significant development, major drug-maker AstraZeneca has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) to conduct a Phase 3 clinical trial of oncology drug Trastuzumab Deruxtecan, which is an antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer.
This comes in the wake of the Phase III clinical trial protocol presented by AstraZeneca at the recent SEC meeting for Oncology and Haematology.
For more details, check out the full story on the link below:
AstraZeneca Gets CDSCO Panel Nod To Conduct Cancer Drug Trastuzumab Deruxtecan Study
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd